Menu Search
Equities

Novozymes A/S

NSIS B:CPH

Novozymes A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)423.70
  • Today's Change-0.300 / -0.07%
  • Shares traded502.45k
  • 1 Year change+23.31%
  • Beta0.7623
Data delayed at least 15 minutes, as of Nov 08 2024 15:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Novozymes A/S's net income fell -17.86% from 494.27m to 405.98m despite flat revenues.
Gross margin46.67%
Net profit margin9.25%
Operating margin13.14%
Return on assets2.96%
Return on equity4.42%
Return on investment3.43%
More ▼

Cash flow in EURView more

In 2023, Novozymes A/S increased its cash reserves by 7.20%, or 10.07m. The company earned 557.42m from its operations for a Cash Flow Margin of 23.20%. In addition the company used 286.36m on investing activities and also paid 253.60m in financing cash flows.
Cash flow per share13.99
Price/Cash flow per share37.20
Book value per share176.57
Tangible book value per share11.88
More ▼

Balance sheet in EURView more

Novozymes A/S has a Debt to Total Capital ratio of 15.31%, a lower figure than the previous year's 36.20%.
Current ratio1.11
Quick ratio0.687
Total debt/total equity0.1808
Total debt/total capital0.1531
More ▼

Growth rates in EUR

Year on year, growth in dividends per share increased 3.18% while earnings per share excluding extraordinary items fell by -17.61%. The positive trend in dividend payments is noteworthy since only some companies in the Chemical Manufacturing industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.46%
Div growth rate (5 year)4.41%
Payout ratio (TTM)0.00%
EPS growth(5 years)-0.2677
EPS (TTM) vs
TTM 1 year ago		--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.